Squamous Cell Carcinoma of Head and Neck Clinical Trials in New Haven, Connecticut

4 studies are recruiting for squamous cell carcinoma of head and neck in New Haven, Connecticut right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

    The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carboplatin in participants with recurrent/metastatic head and neck …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Yale Cancer Center, New Haven, Connecticut
    Locations
    56 in total
    Run by
    Janssen Research & Development, LLC

    See if you can join NCT06385080 on ClinicalTrials.gov

  2. A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

    The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory/metastatic (R/M) head and neck squamous cell carcinoma (…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Yale Cancer Center, New Haven, Connecticut
    Locations
    201 in total
    Run by
    Janssen Research & Development, LLC

    See if you can join NCT07276399 on ClinicalTrials.gov

  3. 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

    This study is being done because both 5-azacytidine and nivolumab can influence the immune system's response to HPV-associated head and neck cancer, and we wish to evaluate whether taking 5-azacytidine will make HPV-associated head and neck cancer more sensitive to treatment with nivolumab. 5-Azacy…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Yale University, New Haven, Connecticut
    Run by
    Barbara Burtness

    See if you can join NCT05317000 on ClinicalTrials.gov

  4. Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

    This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indicat…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Yale, New Haven, Connecticut
    Locations
    15 in total
    Run by
    IO Biotech

    See if you can join NCT05280314 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.